Also, out-of-pocket costs per hospitalization soar, AstraZeneca seeks to extend Crestor patent under the Orphan Drug Act and Virginia Mason's CEO decides to stay after all.
HeartWare International Inc. (NSDQ:HTWR) shares continued their fall for the second straight day on concerns over the higher-than-expected rate of blood clots in a clinical trial of its mechanical heart pump. The Framingham, Mass.-based company said Friday that a 250-patient study of its HVAD Left Ventricular Assist system showed a 9 percent thrombosis rate. Results […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
HeartWare International Inc. files a pre-market approval application with the Food & Drug Administration for a ventricular assist device designed as a bridge-to-transplant system. HeartWare International Inc. (NSDQ:HTWR) filed a pre-market approval application with the Food & Drug Administration for its cardiac assist device. The Framingham, Mass.-based company’s ventricular assist system is designed to provide […]
HeartWare International Inc. (NASDAQ:HTWR) closed a $143 million debt offering and announced the sale of $81.3 million worth of its stock by an investment firm. The Framingham, Massachusetts-based cardiac assist firm said it sold $143.8 million worth of the convertible senior notes, including $18.8 million in an over-allotment purchased by underwriter J.P. Morgan Securities LLC. […]
HeartWare International Inc. (NSDQ: HTWR) won a pair of approvals from the Food & Drug Administration for clinical trials of its cardiac assist device.